Liquidia Corporation (LQDA) - Stock Analysis

Last updated: Jun 21, 2026

HealthcareActive

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion.

Loading chart data...

Idea window: 6/23/2026 – 6/30/2026Sector: Healthcare

AI Analyst Overview

Last Price
$78.17
Market Cap
$4.68B
1D Return
+1.63%
YTD Return
+126.65%

Loading chart data...

Valuation Metrics

P/E
209.6
P/B
43.1
P/S
16.3
EV/EBITDA
95.0
Div Yield
—

Fundamental Analysis

8.0

Key Financial Insights: • Liquidity Strength • Cash Flow Rebound • Rich Valuation LQDA posted a strong quarter with improved liquidity, positive free cash flow, and sharply better margins, but its rich valuation and legacy deficit still cap the investment case.

Turnaround
Overvalued

Price Behavior

7.0

Key Price Behavior Insights: • Breakout momentum • Near-high consolidation • Volatility risk Support Level: $68.00-$68.70 Resistance Level: $71.50-$72.00 Over the last month, LQDA has broken out sharply and remains constructive near recent highs, but the fast run and nearby resistance suggest it may need a pause before extending higher.

bullish
caution

Sentiment & News

7.0

Key News Insights: • S&P Inclusion • Conference Exposure • Momentum Sentiment Liquidia is gaining positive market traction on momentum-friendly coverage, S&P SmallCap 600 inclusion, and steady conference/pipeline visibility, supporting improving investor attention.

LQDA
Biotech
AI

AI Summary

8.0
Positive

LQDA has shifted from a speculative biotech to a cash-generating commercial story on YUTREPIA, but with the stock already pricing in a lot of success at roughly 211x earnings, the key takeaway is to stay bullish only if prescription growth, reimbursement access, and margins keep compounding fast enough to justify the premium.

CommercialExecution
ValuationRisk
CashFlow
AI summary updated 6 days ago

Description

Liquidia Corporation is a U.S.-based biopharmaceutical company that develops, manufactures and commercializes therapies to address unmet clinical needs. Its portfolio includes an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and it also markets generic treprostinil injection domestically. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Jun 23Jun 30LQDALiquidia Corporation
Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion.
Active+5.6%
Jun 16Jun 23LQDALiquidia Corporation
Constructive biotech momentum with a near-term index catalyst: Q1 2026 net product sales were about $130M, the company posted a third consecutive profitable quarter, and S&P SmallCap 600 inclusion is effective 2026-06-22. Shares are up about 20% over 21 trading days and remain above short-term trend.
Closed+8.9%
Jun 8Jun 15LQDALiquidia Corporation
Commercial biotech momentum supported by strong YUTREPIA execution: latest quarter showed about $130M in net product sales, EPS beat consensus ($0.52 vs. $0.34), profitability improved for a third straight profitable quarter, and the stock is up about 50% over 21 trading days.
Closed+12.4%
Jun 1Jun 8LQDALiquidia Corporation
Biotech/commercial momentum name with strong recent execution: YUTREPIA sales were about $130M-$133M, prescriptions exceeded 4,500, profitability reached a third straight quarter, adjusted EBITDA was positive, and free cash flow was strong. Stock is up about 56% over 21 trading days.
Closed+8.8%
May 22May 29LQDALiquidia Corporation
Strong biotech execution and momentum: Q1 2026 showed about $130M of YUTREPIA net sales, more than 4,500 unique prescriptions, a third straight profitable quarter, and improved cash; stock is up about 66% over 21 trading days.
Closed+1.4%
May 13May 20LQDALiquidia Corporation
Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days.
Closed+7.3%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.